Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Arcoxia

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

30 Women Leaders in UK Healthcare

The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future

- PMLiVE

Merck’s Brexit contingency plan? Stockpile medicines

As UK's Brexit plans remain in disarray, big pharma is making contingency plans

- PMLiVE

Europe’s public-private alliance targets pain management

Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area

- PMLiVE

Keytruda gains NICE clearance in first line bladder cancer

MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

- PMLiVE

EC grants MSD’s Prevymis orphan product designation

The product will gain some market exclusivity benefits in CMV infection

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

- PMLiVE

MSD’s Keytruda wins bladder cancer indication in Japan

Becomes first anti-PD1 approved in the country for previously treated UC

- PMLiVE

MSD supports Jabs for the Boys campaign

Awards HPV Action an educational grant for its HPV awareness work

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

- PMLiVE

MSD to create strong UK discovery centre in London

The pharma group aims to start operations by 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links